Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes

Rosangela Invernizzi; Erica Travaglino; Mara De Amici; Silvia Brugnatelli; Isabella Ramajoli; Bianca Rovati; Chiara Benatti; Edoardo Ascari

doi:10.1016/j.leukres.2004.11.008

Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes

Rosangela Invernizzi, Erica Travaglino, Mara De Amici, Silvia Brugnatelli, Isabella Ramajoli, Bianca Rovati, Chiara Benatti, Edoardo Ascari

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-α, bFGF, IL-1β levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.

Original language	English
Pages (from-to)	641-647
Number of pages	7
Journal	Leukemia Research
Volume	29
Issue number	6
DOIs	https://doi.org/10.1016/j.leukres.2004.11.008
Publication status	Published - Jun 2005

Keywords

Angiogenic cytokines
Apoptosis
Lymphocyte subsets
Matrix metalloproteinases
Myelodysplastic syndromes
Thalidomide

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2004.11.008

Fingerprint Dive into the research topics of 'Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this

Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. / Invernizzi, Rosangela; Travaglino, Erica; De Amici, Mara ; Brugnatelli, Silvia; Ramajoli, Isabella; Rovati, Bianca; Benatti, Chiara; Ascari, Edoardo.

In: Leukemia Research, Vol. 29, No. 6, 06.2005, p. 641-647.

Research output: Contribution to journal › Article › peer-review

@article{dc9e286999974bf78d1c7143099088a1,

title = "Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes",

abstract = "We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-α, bFGF, IL-1β levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.",

keywords = "Angiogenic cytokines, Apoptosis, Lymphocyte subsets, Matrix metalloproteinases, Myelodysplastic syndromes, Thalidomide",

author = "Rosangela Invernizzi and Erica Travaglino and {De Amici}, Mara and Silvia Brugnatelli and Isabella Ramajoli and Bianca Rovati and Chiara Benatti and Edoardo Ascari",

year = "2005",

month = jun,

doi = "10.1016/j.leukres.2004.11.008",

language = "English",

volume = "29",

pages = "641--647",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "6",

}

TY - JOUR

T1 - Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes

AU - Invernizzi, Rosangela

AU - Travaglino, Erica

AU - De Amici, Mara

AU - Brugnatelli, Silvia

AU - Ramajoli, Isabella

AU - Rovati, Bianca

AU - Benatti, Chiara

AU - Ascari, Edoardo

PY - 2005/6

Y1 - 2005/6

N2 - We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-α, bFGF, IL-1β levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.

AB - We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-α, bFGF, IL-1β levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.

KW - Angiogenic cytokines

KW - Apoptosis

KW - Lymphocyte subsets

KW - Matrix metalloproteinases

KW - Myelodysplastic syndromes

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=18044393194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044393194&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2004.11.008

DO - 10.1016/j.leukres.2004.11.008

M3 - Article

C2 - 15863203

AN - SCOPUS:18044393194

VL - 29

SP - 641

EP - 647

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -